Deep Learning Model May Help Expand Lung Screening Programs
The deep learning model, known as Sybil, predicts future lung cancer risk based on a single low-dose chest CT and can identify individuals who would benefit from regular monitoring. Medscape Medical News
Could Your Patients Benefit? New Trials in Lung Cancer
Several studies in lung cancer have started enrolling recently – maybe one of your patients could benefit. Medscape Medical News
Less Invasive NSCLC Surgery Does Not Compromise Survival
A US trial showing that sublobar resection achieves similar survival outcomes as lobar resection could usher in precision lung cancer surgery, says expert. Medscape Medical News
Lung Cancer Risk Rises With A1c, Falls With Medication
Prospective data from about 283,000 cancer-free people in a large database showed a significant positive link between incident lung cancer and A1c in people with diabetes or prediabetes. First Look
Medical Practice Gave 8000 Patients Cancer for Christmas
Instead of expressing a simple expression of joy for the holiday season, one clinic in the UK accidentally informed all 8000 of its patients that that they had aggressive lung cancer with metastases. MDedge News
Atezolizumab Plus Bevacizumab: A New Standard for Some NSCLC?
Encouraging findings with the combination suggest that it could offer a new standard treatment for patients with highly mutated non–small cell lung cancer. Medscape Medical News
Adagrasib (Krazati) Approved for KRAS-Mutated NSCLC
It becomes the second KRAS-targeted therapy for use in patients with non–small cell lung cancer (NSCLC) whose tumors have this mutation. FDA Approvals
Racial Disparities in Lung Cancer Start With Research
Improving lung cancer outcomes in Black communities will take more than lowering the screening age, experts say. Kaiser Health News
FDA Rejects Piziotinib for Certain Types of NSCLC
The drug was not approved for the treatment of patients with previously treated locally advanced or metastatic nonsmall cell lung cancer harboring HER2 exon 20 insertion mutations. Medscape Medical News
Over Half of Targetable NSCLC Patients Miss Out on Correct Tx
Most patients with advanced non–small cell lung cancer (NSCLC) have tumors with actionable mutations, but two thirds of them are not receiving targeted therapy owing to gaps in clinical practice. Medscape Medical News
